Current status and future directions of molecular markers in renal cell carcinoma

Current Opinion in Urology

Volumn 16, Issue 5, 2006, Pages 332-336

  Rini, Brian I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

B7 H1; Carbonic anhydrase IX; Molecular markers; Renal cell carcinoma; Vascular endothelial growth factor

Indexed keywords

B7 ANTIGEN; CARBONATE DEHYDRATASE IX; GLYCOPROTEIN; INTERLEUKIN 2; MOLECULAR MARKER; TUMOR MARKER;

DIAGNOSTIC VALUE; DISEASE MARKER; HUMAN; KIDNEY CARCINOMA; METASTASIS; NOMOGRAM; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

ANTIGENS, CD; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NOMOGRAMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33747198782     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mou.0000240304.96131.44     Document Type: Review

References (15)

1. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166:63-67.
2. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 97:1663-1671.
3. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22:454-463.
4. Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004; 22:3316-3322.
5. Grabmaier K, AdWMC, Verhaegh GW, et al. Strict regulation of CAIX (G250/ MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 2004; 23:5624-5631.
6. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9:802-811.
7. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11:3714-3721. This work supported the work by Bui et al. [6] and highlighted the potential predictive relevance of CAIX expression.
8. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 2005; 104:2084-2091.
9. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004; 101:17174-17179.
10. Schraml P, Struckmann K, Hatz F, et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002; 196:186-193.
11. Kondo K, Yao M, Yoshida M, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002; 34:58-68.
12. Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002; 94:1569-1575.
13. Rini BI, Halabi S, Taylor J, et al. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus antivascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004; 10:2584-2586.
14. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005; 66 (5 Suppl):1-9.
15. Flanigan R. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma: Kim HL, Seligson D, Liu X, Janzen N, Bui MHT, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA, Department of Urologic Oncology, Roswell Park Cancer Institute, Buffalo, NY. Urol Oncol 2006; 24:81. The authors have produced several reports, this one being the most recent, to incorporate molecular markers into prognostic schemas based on clinical factors.